CRPC w/ Bone Metastases VL

Optimizing Multi-Disciplinary Care Teams for Radiopharmaceutical Administration - Neal Shore

Details
Urologist Neal Shore joins Alicia Morgans in a conversation on the multidisciplinary approach and successful incorporation of radium-223 dichloride (radium-223) into the treatment algorithm for men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. Drs. Shore and Morgans talk through the challenges care teams face when planning the administration of radiu...

The Correlation Between Alkaline Phosphatase Decline and Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer in the REASSURE Study - Nicholas James

Details
In this discussion, Nicholas James and Alicia Morgans discuss the relationship between alkaline phosphatase decline and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases treated with radium-223 (Ra-223) in the global real-world REASSURE study. REASSURE is evaluating the long-term safety of Radium 223 in routine clinical practice in...

A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore

Details
Alicia Morgans speaks with Neal Shore about advancements in treating metastatic castration-resistant prostate cancer (mCRPC). They discuss the implications of the newly approved PSMA-RLT lutetium-617, a radiopharmaceutical, adding it to a list of existing therapies such as taxane therapy, PARP inhibitors, and immunotherapies like sipuleucel-T. Dr. Shore emphasizes that monotherapy is no longer acc...

Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff

Details
Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. Dr. Dorff also stresses the impor...

Optimal Sequencing - Should It Include Radium Given Lutetium? - Joe O'Sullivan

Details
Joe O’Sullivan joins Alicia Morgans in a conversation about metastatic castration-resistant prostate cancer and the recent approval of lutetium-PSMA-617. As a radiation oncologist, Dr. O’Sullivan shares his views on effective sequencing of radium-223 and lutetium-177 for patients, especially given previous lines of treatment. Biographies: Joe M. O'Sullivan, MD, FRCPI, FFRRSCI, FRCR, Professor of R...

Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Neal Shore presents the role of radium-223 in the modern treatment armamentarium in metastatic castration-resistant prostate cancer (mCRPC) patients. Biographies: Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, Sout...

Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Bones? APCCC 2022 Presentation - Oliver Sartor

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Oliver Sartor presents on the importance of lifestyle and prevention of complications in advanced prostate cancer focusing on how we should take care of our patient’s bones. Biographies: A. Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director Radiopharmaceutical Trials, Mayo Clinic, Rochester, M...

Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad

Details
In this conversation, Fred Saad and Alicia Morgans discuss treatment sequencing in terms of Radium-223 when treating a minimally symptomatic patient or a maximally symptomatic patient. Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospital Centre (CHUM), Director, Prostate Cancer Research,...

Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone

Details
Brenda Martone and Alicia Morgans delve into the nuanced use of Radium for treating patients with metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Martone emphasizes that Radium is not just for alleviating bone pain but can also address other symptoms like fatigue and loss of appetite. She notes that the drug can be used at any point in the treatment continuum, depending on patient need...

Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan

Details
Alicia Morgans, Neeraj Agarwal, and Ben Maughan discuss the publication of a study on a combination of enzalutamide and radium-223 that evaluated the utility of bone metabolic markers (BMM) as surrogate markers of response to radium-223 in mCRPC. Biographies: Neeraj Agarwal, MD, Clinical Research Innovation, University of Utah Health - Huntsman Cancer Institute, Salt Lake City, UT Benjamin L. Maug...